Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,573 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Biological Control Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Scavenging of Reactive Carbonyl Species by Dietary Flavonoids in Humans

NCT05773794
View directory record Official record
Conditions
Human Health, Reactive Carbonyl Species, Polyphenols
Interventions
Soymilk, green tea, or blueberry, Control group
Dietary Supplement
Lead sponsor
North Carolina Agriculture & Technical State University
Other
Eligibility
25 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 23, 2026, 5:53 PM EDT
Completed Phase 3 Interventional

Recombinant Factor VIIa in Acute Intracerebral Haemorrhage

NCT00127283
View directory record Official record
Conditions
Acquired Bleeding Disorder, Intracerebral Haemorrhage
Interventions
eptacog alfa (activated)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
829 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
77
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 23, 2026, 5:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Teacher Child Interaction Training (TCIT): Randomized Control Trial

NCT04000230
View directory record Official record
Conditions
Behavior, Child
Interventions
TCIT, Booster
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
12 Months and older
Enrollment
622 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
4
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 23, 2026, 5:53 PM EDT
Completed Phase 2 Interventional

Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus

NCT00085969
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo 0.04 mL twice daily, Placebo 0.04 mL once daily, Placebo 0.08 mL once daily, B - Exenatide 10 mcg twice daily, C - Exenatide 10 mcg once daily, Exenatide 20 mcg once daily
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
23
States / cities
La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Oct 23, 2026, 5:53 PM EDT
Active, not recruiting Phase 3 Interventional

Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy

NCT04083339
View directory record Official record
Conditions
Diabetic Cardiomyopathies
Interventions
AT-001, Placebo
Drug
Lead sponsor
Applied Therapeutics, Inc.
Industry
Eligibility
40 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
28
States / cities
Beverly Hills, California • La Jolla, California • Lincoln, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Oct 23, 2026, 5:53 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effectiveness of the Pneumococcal Polysaccharide Vaccine in Military Recruits

NCT02079701
View directory record Official record
Conditions
Pneumonia, Acute Respiratory Disease
Interventions
23-valent pneumococcal vaccine, Placebo
Biological
Lead sponsor
Naval Health Research Center
Federal
Eligibility
Not listed
Enrollment
152,723 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2007
U.S. locations
5
States / cities
San Diego, California • Great Lakes, Illinois • Fort Leonard Wood, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Oct 23, 2026, 5:53 PM EDT
Completed Phase 1Phase 2 Interventional Results available

AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin

NCT00147225
View directory record Official record
Conditions
Solid Tumors, Advanced Cancer
Interventions
AMG 531, Carboplatin, Adriamycin, Ifosfamide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Oct 23, 2026, 5:53 PM EDT
Enrolling by invitation Not applicable Interventional

Biologic Augmentation With Mesenchymal Stem Cells in Patients Undergoing Anterior Cruciate Ligament Reconstruction

NCT04650568
View directory record Official record
Conditions
Anterior Cruciate Ligament Injury, Anterior Cruciate Ligament Rupture
Interventions
Autologous Bone Marrow Derived Mesenchymal Stem Cells, Sham incision
Device · Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 23, 2026, 5:53 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis

NCT05782335
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 23, 2026, 5:53 PM EDT
Recruiting Phase 1Phase 2 Interventional

Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer

NCT06307548
View directory record Official record
Conditions
Locally Advanced Colorectal Carcinoma, Recurrent Colorectal Carcinoma, Stage III Colorectal Cancer
Interventions
Aminolevulinic Acid, Biospecimen Collection, Computed Tomography, Fluorescence-Guided Surgery, Magnetic Resonance Imaging, Photodynamic Therapy, Surgical Procedure
Drug · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 23, 2026, 5:53 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)

NCT00436826
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Cladribine, Placebo, Interferon-beta (IFN-beta)
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
21
States / cities
Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2020 · Synced Oct 23, 2026, 5:53 PM EDT
Terminated Phase 2 Interventional Results available

Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis

NCT01758588
View directory record Official record
Conditions
Myelofibrosis
Interventions
Peginterferon alfa-2a
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Atlanta, Georgia • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 23, 2026, 5:53 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Preventing Postpartum Depression in African American Home Visiting Clients

NCT01175603
View directory record Official record
Conditions
Depression
Interventions
Mothers and Babies Course (Adapted for Baltimore Home Visiting Programs)
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
14 Years to 50 Years · Female only
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
4
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 7, 2016 · Synced Oct 23, 2026, 5:53 PM EDT
Completed Phase 2 Interventional Results available

DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact

NCT00789477
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Laser Photocoagulation, Intravitreal Aflibercept Injection
Procedure · Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
42
States / cities
Artesia, California • Beverly Hills, California • Mountain View, California + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2014 · Synced Oct 23, 2026, 5:53 PM EDT
Completed Phase 2 Interventional Results available

Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer

NCT01373294
View directory record Official record
Conditions
Bladder Cancer
Interventions
Bacille Calmette-Guerrin (BCG), Lenalidomide
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 23, 2026, 5:53 PM EDT
Completed Phase 1 Interventional

GLP-1 Agonism for Blocking Cocaine Euphoria and Self-Administration

NCT02302976
View directory record Official record
Conditions
Cocaine Dependence
Interventions
cocaine hydrochloride, exenatide, placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 23, 2026, 5:53 PM EDT
Completed Phase 4 Interventional Results available

Assess the Penumbra System in the Treatment of Acute Stroke

NCT01429350
View directory record Official record
Conditions
Ischemic Stroke
Interventions
intravenous (IV) recombinant human tissue plasminogen activator (rtPA), Penumbra System
Drug · Device
Lead sponsor
Penumbra Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
4
States / cities
Denver, Colorado • Gainesville, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Oct 23, 2026, 5:53 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Botulinum Toxin A for the Treatment of Chronic Lumbar Back Pain

NCT00404417
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Botulinum Toxin A / Placebo, Botulinum Toxin A / Botulinum Toxin A, Placebo / Botulinum Toxin A, Placebo / Placebo
Drug
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
18 Years to 70 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 23, 2026, 5:53 PM EDT
Completed Phase 4 Interventional Results available

Reduction of Bladder Injection Pain With Belladonna Opiate Suppository

NCT02600715
View directory record Official record
Conditions
Overactive Bladder, Urinary Urge Incontinence, Urinary Bladder, Neurogenic, Painful Bladder Syndrome
Interventions
Onabotulinumtoxin A (BoNT), belladonna, Morphine, Placebo, Active B&O suppository of belladonna
Drug
Lead sponsor
Edgar LeClaire, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Oct 23, 2026, 5:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Entre Herman@s: Promoting Health Among Latino MSM

NCT05805306
View directory record Official record
Conditions
HIV Infections
Interventions
Entre Herman@s, Vaccines for Health
Behavioral
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years to 39 Years
Enrollment
288 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 23, 2026, 5:53 PM EDT
Completed Not applicable Interventional

A Pilot Clinical Trial of Sympathetic Blockade With Botulinum Toxin Type A to Treat Complex Regional Pain Syndrome (CRPS): a Randomized, Double-Blind, Controlled, Crossover Trial.

NCT00637533
View directory record Official record
Conditions
Pain
Interventions
Lumbar sympathetic block with Botulinum Toxin type A
Procedure
Lead sponsor
Stanford University
Other
Eligibility
21 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 19, 2011 · Synced Oct 23, 2026, 5:53 PM EDT
Completed Not applicable Interventional

Improving Health Behavior and Outcomes After Angioplasty

NCT00248976
View directory record Official record
Conditions
Angioplasty
Interventions
Net-present value of individual health behaviors in years
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Oct 23, 2026, 5:53 PM EDT
Terminated Not applicable Interventional

Cryotherapy in the Prevention of Chemotherapy-Induced Mucositis in Stem Cell Transplant

NCT02326675
View directory record Official record
Conditions
Mucositis, Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Stomatitis
Interventions
Ice, Normal Saline Solution
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Oct 23, 2026, 5:53 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1

NCT00577577
View directory record Official record
Conditions
Myotonic Dystrophy Type 1
Interventions
rhIGF-I/rhIGFBP-3, placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
21 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
12
States / cities
Orange, California • Sacramento, California • Kansas City, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2022 · Synced Oct 23, 2026, 5:53 PM EDT